Immunotherapies for NSCLC: Are we cutting the gordian helix?

Anticancer Research

Volumn 35, Issue 11, 2015, Pages 5745-5757

  Dempke, Wolfram C M ^a,b   Sellmann, Ludger ^c   Fenchel, Klaus ^d   Edvardsen, Klaus ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ASTRAZENECA   (United Kingdom)

^c Medical Oncology Unit   (Germany)

^d Asklepios Medical School Hamburg   (Germany)

Author keywords

Clinical outcome; Immunotherapies; Molecular biology; NSCLC; Review

Indexed keywords

ATEZOLIZUMAB; BEVACIZUMAB; COBIMETINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; ERLOTINIB; GEFITINIB; IPILIMUMAB; LIRILUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; TICILIMUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGNOSIS;

EID: 84946092622     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics 2014. CA: A Cancer Journal for Clinicians 64: 9-29, 2014.
2. Fumarola C, Bonelli MA, Petronini PG and Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non-small cell lung cancer. Biochem Pharmacol 90: 197-207, 2014.
3. Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC and Proia DA: The HSP90 inhibitor ganetespibpotentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target Oncol: published electronically (2014).
4. Chen DS and Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity DOI: org/10.1016/j.immuni. 2013.07.012, 2013.
5. Sznol M and Chen L: Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19: 1021-1034, 2013.
6. Callahan MK, Postow MA and Wolchok JD: CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Frontiers Oncol 4: 1-6, 2015.
7. Rudd CE, Taylor A and Schneider H: CD28 and CTLA-4 correceptor expression and signal transduction. Immunol Rev 229: 467-477, 2009.
8. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C and Ribas A: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-583, 2014.
9. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2013.
10. Keir ME, Francisco LM and Sharpe AH: PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 192: 309-314, 2007.
11. Chen DS, Irving BA and Hodi FS: Molecular Pathways: Nextgeneration immunotherapy-inhibiting programmed deathligand 1 and programmed death-1. Clin Cancer Res 18: 6580-6587, 2012.
12. McDermott DF and Atkins MB: PD-1 as a potential target in cancer therapy. Cancer Med 2: 662-673, 2013.
13. Zhang Y, Huang S, Gong D, Qin Y and Shen Q: Programmed death-1 upregulation is correlated with dysfunction of tumor-Infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 7: 389-395, 2010.
14. Harvey RD: Immunologic clinical effects of targeting PD-1 in lung cancer. Nature 96. 214-223, 2014
15. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO and T(regs) in the melanoma environment is driven by CD8(+) T cells. Sci Transl Med 5: 200ra116, 2013.
16. Zou W and Chen L: Inhibitory B7-family molecules in the tumor microenviroment. Nat Rev Immunol 8: 467-477, 2008.
17. Rech AJ and Vonderheide RH: Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenviroment. Cancer Discov 3: 1355-1363, 2013.
18. Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y and Ouyang X: Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma. Clinical Lung Cancer DOI: 10.1016/j.cllc.2015.02.002, 2015.
19. Chen YB, Mu CY and Huang JA: Clinical significance of programmed death-1 ligand-1 expression in patients with nonsmall cell lung cancer: A 5-year-follow-up study. Tumori 98: 751-755, 2012.
20. Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570, 2011.
21. Gaiha GD, McKim KJ, Woods M, Pertel T, Rohrbach J, Barteneva N, Chin CR, Liu D, Soghoian DZ, Cesa K, Wilton S, Waring MT, Chicoine A, Doering T, Wherry EJ, Kaufmann DE, Lichterfeld M, Brass AL and Walker BD: Dysfunctional HIV-specific CD8+ T cell proliferation is associated with increased caspase-8 activity and mediated by necroptosis. Immunity 18: 1001-1012, 2014.
22. Leach DR, Krummel MF and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736, 1996.
23. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS USA 99: 12293-12297, 2002.
24. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R and Hodi FS: Guidelines for the evaluation of immune therapy activity in solid tumors: Immun-related response criteria. Clin Cancer Res 15: 7412-7420, 2009.
25. Garon EB, Gandhi L, Rizvi N, Hui R, Balmanoukian AS and Patnaik A: Antitumor activity of pembrolizumab (Pembro; MK-3575) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol 25 (Suppl 5): 1-41, 2014.
26. Soria JC, Gettinger S, Gordon M, Heist RS, Horn L and Spigel DR: Biomarkers associated with clinical activity of PD-L1 blockade in non-small cell lung cancer (NSCLC) patients (pts) in a phase I study of MPDL3280A. Ann Oncol 25 (Suppl 5): 426-470, 2014.
27. Soria JC, Cruz C, Bahleda R, Delord JP, Horn L and Herbst RS: Clinical efficacy, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer: Additional analyses from a clinical study of the engeneered antibody MPDL3280A (anti-PD-L1). Proceedings of the European Cancer Congress; 2013 Sept 27-Oct 1, Amsterdam, The Netherlands, Abstract 3408.
28. Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li X, Robbins PB, Vasselli J, Ibrahim RA and Joseph S: Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody in patients with NSCLC. J Clin Oncol 32 (Suppl): 5s, 2014.
29. Lynch TJ, Bondarenko I, Luft A, Servatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM and Reck M: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30: 2046-2054, 2012.
30. Zatloukal P, Heo DS, Park K, Kang J, Butts C, Bradford S,Graziano S, Huang B and Healey D: Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care following first line platinum-based therapy in patients with advanced non-small cell lung cancer. J Clin Oncol 27 (Suppl): 15s, 2009.
31. Gettinger SN, Horn L, Ghandi L, Spigel DR, Antonia SJ and Rizvi NA: Long-term survival, clinical activity, and safety of nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol 90: S34, 2014.
32. Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ and Ramalingam SS: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibior, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 16: 257-265, 2015.
33. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, ArénFrontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B and Spigel DR: Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. N Engl J Med DOI: 10.1056/NEJMoa1504627, 2015.
34. http://news.bms.com/press-release/checkmate-057-pivotal-phaseiii-opdivo-nivolumab-lung-cancer-trial-stopped-early (assessed May 20, 2015).
35. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, and Brahmer JR: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 10.1200./JCO.2014.58.3708, 2015.
36. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K and Gandhi L: Pembrolizumab for the treatment of non-small-cell lung cancer. New Engl J Med DOI: 10.1056/NEJMoa1501824, 2015.
37. Scagliotti GV, Bironzo P and Vansteenkiste JF: Addressing the unmet need in lung cancer: The potential of immuno-Oncology. Cancer Treat Rev DOI: 10.1016/j.ctrv.2015.04.001, 2015.
38. Spira IA, Park K, Mazieres J, Vansteenkiste JF, Rittmeyer A, Ballinger M, Waterkamp D, Kowanetz M, He P and Fehrenbacher L: Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3208A versus docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol 33 (Suppl 15S): 424s, 2015.
39. Antonia SJ, Gettinger S, Goldman J, Chow LQ, Juergens R and Borghaei H: Safety and efficacy of first-Line nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC). Int J Radiat Oncol 90: S32, 2014.
40. Carbone DP, Socinski MA, Chen AC, Bhagavatheeeswaran P, Reck M and Paz-Ares L: A phase III randomized, open-label trial of nivolumab (Anti-PD-1; B;S-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1 + Non-small Cell Lung Cancer (NSCLC). J Clin Oncol 32 (Suppl 5): TPS8128, 2014.
41. Antonia SJ, Goldberg S, Balmanoukian A, Sanborn RE, Steele K, Narwal R, Robbins PB, Gu Y, Karakunnel JJ and A. Rizvi NA: Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J Clin Oncol 33 (Suppl): #3104, 2015.
42. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG and Vignali DA: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-Cell function to promote tumor immunescape. Cancer Res 72: 917-927, 2012.
43. Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, Smothers J and Hoos A: The BRAF and MEK inhibitors dabrafenib and trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 21: 1639-1651, 2015.
44. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL,Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G and Wong KK: Activation of the PD-1 pathway contributes to immune escape in EGFRdriven lung tumors. Cancer Discovery DOI: 10.1158/2159-9290.CD-13-0310, 2013.
45. Spranger S, Bao R and Gajewsky TF: Melanoma-intrinsic ?-catenin signalling prevents anti-tumor immunity. Nature doi: 10.1038/nature14404, 2015.
46. D'Inecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L,Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L and Cappuzzo F: PD-1 and PD-L1 expression in moleculary selected non-small-cell lung cancer patients. Br J Cancer 12: 95-102, 2015.
47. Soria JC, Marabelle A, Brahmer JR and Gettinger S: Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res 21: 2256-2262, 2015.
48. Gainor JF, Sequist LV, Shaw AT, Azzoli CG, Piotrowska Z, Huynh T,Fulton L, Schultz K, Hata AN and Engelman JA: Clinical correlation and frequency of programmed cell death ligand-1 (PD-L1) expression in EGFR-mutated and ALKrearranged non-small cell lung cancer (NSCLC). J Clin Oncol 33 (Suppl 15S): 425s, 2015.
49. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y and Okamoto I: Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-smallcell lung cancer. Ann Oncol 25: 1935-1940, 2014.
50. Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, Li G, Tang W, Peng P and Zhang L:The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget, published electronically, 2015.
51. Gettinger S, Chow LQ, Borghaei H, Shen Y, Harbison C and Chen AC: Safety and response with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol 90: S34, 2014.
52. Creelan B, Chow LQ, Kim DW, Kim SW, Yeh TC, Narwal R, Tang W, Karakunnel JJ and Gibbons DL: Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 PDL1 antibody, combined with gefitinib in patients with NSCLC. J Clin Oncol 33 (Suppl): 3047, 2015.
53. Anagnostou VK and Brahmer JR: Cancer Immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res 21: 976-984, 2015.
54. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK and Kirkwood JM: New challenges in endpoints for drug development in advanced melanoma. Clin Cancer 18: 336-341, 2012.